StocksFundsScreenerSectorsWatchlists
VCYT

VCYT - Veracyte Inc Stock Price, Fair Value and News

19.05USD-0.31 (-1.60%)Delayed as of 16 Apr 2024, 02:05 pm ET

Market Summary

VCYT
USD19.05-0.31
Delayedas of 16 Apr 2024, 02:05 pm
-1.60%

VCYT Alerts

  • 1 major insider sales recently.

VCYT Stock Price

View Fullscreen

VCYT RSI Chart

VCYT Valuation

Market Cap

1.5B

Price/Earnings (Trailing)

-19.53

Price/Sales (Trailing)

4.03

EV/EBITDA

-25.03

Price/Free Cashflow

42.42

VCYT Price/Sales (Trailing)

VCYT Profitability

Operating Margin

90.01%

EBT Margin

-21.22%

Return on Equity

-7.13%

Return on Assets

-6.67%

Free Cashflow Yield

2.36%

VCYT Fundamentals

VCYT Revenue

Revenue (TTM)

361.1M

Rev. Growth (Yr)

22.29%

Rev. Growth (Qtr)

8.98%

VCYT Earnings

Earnings (TTM)

-74.4M

Earnings Growth (Yr)

-636.03%

Earnings Growth (Qtr)

4.47%

Breaking Down VCYT Revenue

52 Week Range

18.7430.52
(Low)(High)

Last 7 days

-6.4%

Last 30 days

-8.2%

Last 90 days

-27.3%

Trailing 12 Months

-11.7%

How does VCYT drawdown profile look like?

VCYT Financial Health

Current Ratio

4.66

VCYT Investor Care

Shares Dilution (1Y)

4.04%

Diluted EPS (TTM)

-1.02

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023311.2M328.6M343.1M361.1M
2022250.6M268.4M283.6M296.5M
2021123.1M157.5M186.7M219.5M
2020122.0M112.5M112.7M117.5M
2019101.5M108.9M116.4M120.4M
201875.6M79.9M85.9M92.0M
201768.0M71.7M70.6M72.0M
201651.8M54.6M60.9M65.1M
201541.9M45.2M47.7M49.5M
201425.0M28.6M32.8M38.2M
201314.5M17.1M19.5M21.9M
20124.9M7.1M9.4M11.6M
20110002.6M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Veracyte Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 01, 2024
eastham karin
acquired
131,900
13.19
10,000
-
Apr 01, 2024
eastham karin
sold
-216,528
21.6528
-10,000
-
Mar 15, 2024
stapley marc
sold (taxes)
-125,988
21.1
-5,971
chief executive officer
Mar 15, 2024
chambers rebecca
acquired
-
-
4,318
chief financial officer
Mar 15, 2024
stapley marc
acquired
-
-
11,780
chief executive officer
Mar 15, 2024
chambers rebecca
sold (taxes)
-46,187
21.1
-2,189
chief financial officer
Mar 06, 2024
wygant jonathan
acquired
-
-
23,942
vp, chief accounting officer
Mar 06, 2024
mcguire annie
acquired
-
-
49,880
svp, general counsel
Mar 06, 2024
febbo phillip g.
acquired
-
-
39,904
chief scientific & med officer
Mar 06, 2024
leite john
acquired
-
-
49,880
chief commercial officer-clia

1–10 of 50

Which funds bought or sold VCYT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 12, 2024
BALDWIN BROTHERS LLC/MA
unchanged
-
-268
1,108
-%
Apr 11, 2024
Opal Wealth Advisors, LLC
new
-
289
289
-%
Apr 11, 2024
CONTRAVISORY INVESTMENT MANAGEMENT, INC.
sold off
-100
-243,436
-
-%
Apr 09, 2024
MASSMUTUAL TRUST CO FSB/ADV
new
-
133
133
-%
Apr 09, 2024
MATHER GROUP, LLC.
new
-
3,576
3,576
-%
Apr 05, 2024
FIRST HAWAIIAN BANK
sold off
-100
-392,018
-
-%
Apr 05, 2024
CWM, LLC
reduced
-46.24
-16,000
13,000
-%
Apr 05, 2024
LOS ANGELES CAPITAL MANAGEMENT LLC
added
117
199,077
463,366
-%
Apr 05, 2024
GAMMA Investing LLC
added
190
1,611
2,637
-%
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
added
27.31
73,015
201,457
-%

1–10 of 44

Are Funds Buying or Selling VCYT?

Are funds buying VCYT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own VCYT
No. of Funds

Unveiling Veracyte Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
9.75%
7,118,211
SC 13G/A
Feb 12, 2024
artisan partners limited partnership
4.4%
3,217,728
SC 13G/A
Feb 08, 2024
wellington management group llp
9.68%
7,068,435
SC 13G/A
Jan 29, 2024
ark investment management llc
10.48%
7,655,603
SC 13G/A
Jan 24, 2024
blackrock inc.
9.8%
7,161,866
SC 13G/A
Jan 22, 2024
state street corp
4.26%
3,108,639
SC 13G/A
Jun 09, 2023
wellington management group llp
10.01%
7,248,889
SC 13G/A
Feb 10, 2023
artisan partners limited partnership
5.2%
3,761,031
SC 13G/A
Feb 10, 2023
ark investment management llc
11.57%
8
SC 13G/A
Feb 10, 2023
invesco ltd.
0.4%
313,974
SC 13G/A

Recent SEC filings of Veracyte Inc

View All Filings
Date Filed Form Type Document
Apr 02, 2024
4
Insider Trading
Apr 01, 2024
144
Notice of Insider Sale Intent
Mar 22, 2024
424B7
Prospectus Filed
Mar 22, 2024
8-K
Current Report
Mar 19, 2024
4
Insider Trading
Mar 19, 2024
4
Insider Trading
Mar 08, 2024
4
Insider Trading
Mar 08, 2024
4
Insider Trading
Mar 08, 2024
4
Insider Trading
Mar 08, 2024
4
Insider Trading

Peers (Alternatives to Veracyte Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
39.7B
6.8B
0.01% -33.89%
-8.42
5.79
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.6B
1.8B
-1.06% -27.57%
-42.25
10.17
76.23% 61.08%
17.3B
2.4B
9.12% -7.56%
103
7.14
15.42% 18.43%
12.0B
3.7B
-8.48% -28.30%
20.07
3.25
8.87% 75.42%
MID-CAP
6.2B
396.6M
-9.27% -36.41%
-11.74
15.65
425.83% 18.94%
4.5B
-
-6.46% 74.90%
-6.94
60.35
54.84% -34.79%
3.2B
270.6M
-9.62% -0.34%
-13.52
11.95
440.80% -27.84%
3.0B
240.7M
-15.06% -21.14%
-10.03
12.36
-1.03% -92.09%
2.8B
726.4M
-8.60% -6.11%
-45.41
3.83
40.45% 71.62%
SMALL-CAP
1.8B
398.2M
-4.17% -12.95%
25.42
4.56
85.90% -14.05%
576.6M
983.7M
-22.12% -55.02%
-1.06
0.59
-50.36% 17.16%
448.6M
881.7K
-2.13% 345.78%
-10.06
466.16
-77.61% -5.33%
256.8M
4.9M
2.33% 7.75%
-1.9
52.78
-54.97% 51.72%
6.7M
2.1M
82.86% 81.13%
-0.25
2.14
-13.45% 66.37%

Veracyte Inc News

Latest updates
Defense World10 hours ago
Yahoo Finance02 Apr 202407:00 am
Simply Wall St26 Feb 202408:00 am
Yahoo Finance23 Feb 202408:00 am
Yahoo Finance23 Feb 202408:00 am
Seeking Alpha22 Feb 202408:00 am

Veracyte Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue9.0%98,199,00090,108,00090,322,00082,422,00080,297,00075,592,00072,864,00067,783,00067,336,00060,370,00055,105,00036,703,00034,536,00031,121,00020,704,00031,122,00029,730,00030,973,00030,136,00029,529,00025,750,000
Cost Of Revenue-----------------9,673,0009,114,0008,777,0008,513,0008,704,000
Costs and Expenses9.7%133,706,000121,847,00098,373,00092,920,00085,717,00085,272,00083,597,00083,031,00079,669,00077,051,00062,579,00082,118,00042,608,00035,187,00031,755,00043,322,00037,927,00032,736,00033,236,00031,596,00028,807,000
  S&GA Expenses3.8%25,260,00024,344,00025,756,00026,130,00024,127,00025,678,00024,001,00023,754,00022,212,00021,670,00019,662,00016,296,00013,149,00010,955,00010,701,00017,584,00014,183,00013,088,00013,943,00012,477,00010,066,000
  R&D Expenses40.2%18,673,00013,322,00012,541,00012,769,00011,287,00010,773,0009,377,0009,166,00010,252,0008,006,0006,249,0005,336,0004,586,0004,042,0004,169,0004,407,0004,443,0003,643,0003,330,0003,435,0003,125,000
EBITDA Margin-Infinity%-0.14--0.01-0.01-0.04-0.07-0.09-0.11-0.28-0.34-0.36-0.49-0.23--------
Interest Expenses-----9,000-----27,00063,000--76,00055,00065,00055,000-264,00058,000235,000303,000536,000
Income Taxes-971.7%-2,143,500-200,000100,000-395,500-152,000-100,000-3,000-760,000-1,400,000-152,000-3,800,000---------
Earnings Before Taxes-2.4%-30,472,000-29,772,000-8,277,000-8,091,000-3,441,000-8,875,000-9,647,000-14,464,000-11,317,000-15,479,000-9,190,000-45,663,000-8,044,000-4,124,000-11,025,000-11,716,000-----
EBT Margin-46.9%-0.21-0.14-0.09-0.10-0.12-0.16-0.19-0.20-0.37-0.42-0.43-0.56---------
Net Income4.5%-28,293,000-29,618,000-8,402,000-8,091,000-3,844,000-8,723,000-9,532,000-14,461,000-10,528,000-14,129,000-9,038,000-41,868,000-8,044,000-4,124,000-11,025,000-11,716,000-7,458,000-730,000-2,494,000-1,917,000-3,105,000
Net Income Margin-41.6%-0.21-0.15-0.09-0.10-0.12-0.15-0.18-0.19-0.34-0.39-0.40-0.53---------
Free Cashflow14.8%13,055,00011,369,00013,002,000-3,165,0007,872,0005,312,000-2,873,000-11,325,0007,605,000-3,205,000360,000-41,757,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-0.9%1,1151,1251,1611,1571,1561,1261,1441,1741,1881,1861,0271,025457454257267275260252124121
  Current Assets5.3%28627125925224923923523824322937136237637017318118822822091.0097.00
    Cash Equivalents6.9%21620219117815417115416417316532832535034614815416019619368.0079.00
  Inventory1.5%16.0016.0012.0013.0014.0014.0015.0012.0011.0010.007.006.005.004.007.006.007.007.005.004.003.00
  Net PPE-----------12.0011.009.009.009.009.009.008.008.008.009.00
  Goodwill1.4%7036936997006966776907047087144724753.003.003.003.003.001.001.001.001.00
Liabilities-0.1%71.0071.0078.0076.0081.0078.0080.0088.0091.0079.0056.0051.0036.0031.0031.0037.0036.0029.0028.0040.0041.00
  Current Liabilities7.0%61.0057.0058.0056.0063.0058.0059.0063.0064.0050.0036.0033.0017.0014.0013.0019.0017.0017.0015.0014.0013.00
  Long Term Debt----------1.001.001.001.001.001.001.001.001.001.0013.0024.00
    LT Debt, Current------1.001.001.001.00-----------1.00
    LT Debt, Non Current----------1.001.001.001.001.001.001.001.001.001.0013.0024.00
Shareholder's Equity-0.9%1,0441,0541,0831,0811,0751,0481,0641,0851,0971,10797197442142322623023923122484.0080.00
  Retained Earnings-6.4%-468-439-410-401-393-389-381-371-357-346-332-323-281-273-269-258-246-239-238-236-234
  Additional Paid-In Capital0.5%1,5361,5281,5211,5101,5001,4921,4831,4771,4691,4621,3041,298703696496489486470463320314
Shares Outstanding0.4%73.0073.0073.0072.0072.0072.0071.0071.0068.0070.0065.0063.00---------
Float---1,700---1,400---2,700---1,300---1,300--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations9.7%15,55214,17116,671-2,1729,7447,026-363-8,8728,446-1,3931,887-40,5612,2611,752-8,423-5,3011,790-1,556-2,455-1,011-1,226
  Share Based Compensation3.4%7,5127,26310,3817,9856,8677,2835,9396,6456,7327,8684,0643,8553,6413,0893,3602,9052,8422,6402,5661,7591,533
Cashflow From Investing10.9%-2,497-2,802-3,66924,080-26,4348,807-9,307-2,453385-165,4571,473-575,607-888-1,635-649-665-41,100-226-658-749-454
Cashflow From Financing486.4%6451103971,68593.001,486-75.001,9901733,2151,920591,0122,911197,5133,390-2192,9654,797127,919-8,3941,829

VCYT Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue:   
Total revenue$ 361,051$ 296,536$ 219,514
Operating expenses:   
Research and development57,30540,60329,843
Selling and marketing101,49097,56079,840
General and administrative86,22973,200101,353
Impairment of long-lived assets68,3493,3180
Intangible asset amortization20,57021,35415,981
Total operating expenses446,846337,617301,417
Loss from operations(85,795)(41,081)(81,903)
Other income, net9,1834,654254
Loss before income tax benefit(76,612)(36,427)(81,649)
Income tax (benefit) provision(2,208)133(6,086)
Net loss$ (74,404)$ (36,560)$ (75,563)
Net loss per common share, basic (in USD per share)$ (1.02)$ (0.51)$ (1.11)
Net loss per common share, diluted (in USD per share)$ (1.02)$ (0.51)$ (1.11)
Shares use to compute net loss per common share, basic (in shares)72,644,48771,549,20467,890,328
Shares use to compute net loss per common share, diluted (in shares)72,644,48771,549,20467,890,328
Testing revenue   
Revenue:   
Total revenue$ 326,542$ 250,544$ 188,182
Operating expenses:   
Cost of revenue88,91375,31758,860
Product revenue   
Revenue:   
Total revenue15,58812,63211,464
Operating expenses:   
Cost of revenue8,6667,8205,887
Biopharmaceutical and other revenue   
Revenue:   
Total revenue18,92133,36019,868
Operating expenses:   
Cost of revenue$ 15,324$ 18,445$ 9,653

VCYT Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 216,454,000$ 154,247,000
Short-term investments024,605,000
Accounts receivable40,378,00044,021,000
Supplies and inventory16,128,00014,294,000
Prepaid expenses and other current assets12,661,00011,469,000
Total current assets285,621,000248,636,000
Property, plant and equipment, net20,584,00017,702,000
Right-of-use assets, operating leases10,277,00013,160,000
Intangible assets, net88,593,000174,866,000
Goodwill702,984,000695,891,000
Restricted cash876,000749,000
Other assets5,971,0005,418,000
Total assets1,114,906,0001,156,422,000
Current liabilities:  
Accounts payable12,943,00011,911,000
Accrued liabilities38,427,00037,774,000
Current portion of deferred revenue2,008,0002,613,000
Current portion of acquisition-related contingent consideration2,657,0006,060,000
Current portion of operating lease liabilities5,105,0004,070,000
Current portion of other liabilities101,000186,000
Total current liabilities61,241,00062,614,000
Deferred tax liability734,0004,531,000
Acquisition-related contingent consideration, net of current portion518,0002,498,000
Operating lease liabilities, net of current portion7,525,00010,648,000
Other liabilities786,000931,000
Total liabilities70,804,00081,222,000
Commitments and contingencies
Stockholders' equity:  
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of December 31, 2023 and 202200
Common stock, $0.001 par value; 125,000,000 shares authorized, 73,264,738 and 71,959,454 shares issued and outstanding as of December 31, 2023 and 2022, respectively73,00072,000
Additional paid-in capital1,536,168,0001,500,191,000
Accumulated deficit(468,121,000)(393,717,000)
Accumulated other comprehensive loss(24,018,000)(31,346,000)
Total stockholders' equity1,044,102,0001,075,200,000
Total liabilities and stockholders' equity$ 1,114,906,000$ 1,156,422,000
VCYT
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEveracyte.com
 INDUSTRYBiotechnology
 EMPLOYEES787

Veracyte Inc Frequently Asked Questions


What is the ticker symbol for Veracyte Inc? What does VCYT stand for in stocks?

VCYT is the stock ticker symbol of Veracyte Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Veracyte Inc (VCYT)?

As of Mon Apr 15 2024, market cap of Veracyte Inc is 1.45 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VCYT stock?

You can check VCYT's fair value in chart for subscribers.

What is the fair value of VCYT stock?

You can check VCYT's fair value in chart for subscribers. The fair value of Veracyte Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Veracyte Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VCYT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Veracyte Inc a good stock to buy?

The fair value guage provides a quick view whether VCYT is over valued or under valued. Whether Veracyte Inc is cheap or expensive depends on the assumptions which impact Veracyte Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VCYT.

What is Veracyte Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, VCYT's PE ratio (Price to Earnings) is -19.53 and Price to Sales (PS) ratio is 4.03. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VCYT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Veracyte Inc's stock?

In the past 10 years, Veracyte Inc has provided 0.038 (multiply by 100 for percentage) rate of return.